A PPQ Protocol Is Not Commercial Batch Release: Stage 2 Versus Stage 3 Records

A signed PPQ protocol is not commercial batch release

For one qualification lot, what records are still missing before anyone treats a completed Stage 2 process performance qualification (PPQ) protocol as authorization for commercial distribution? A signed PPQ protocol—and even an approved PPQ execution summary report—is not a commercial batch-release certificate. Mark four fields independently as present, missing, or unknown: (1) Stage 2 PPQ protocol completion and process-evaluation report; (2) whether the approved protocol actually designs concurrent release, with rationale and lot-release criteria, if anyone proposes distribution before the study is fully executed; (3) quality-control-unit commercial disposition under 21 CFR 211.165 and 21 CFR 211.22 for this lot; and (4) whether a Stage 3 continued process verification (CPV) program under 21 CFR 211.180(e) exists for routine production. Concurrent-release design is not a standing fourth packet that every lot must carry. Stage 3 does not release the historical lot.

Across biopharma commercialization teams, contract development and manufacturing organization (CDMO) technical operations, and in-licensing due diligence reviews, a recurring operational shortcut is to treat a bound, signed PPQ protocol and a qualification summary report as if they closed commercial release. That administrative assumption conflates a study protocol documenting the capability of a manufacturing process design with the legal release disposition of an individual drug product lot. The PPQ protocol answers whether the manufacturing system is reproducible under commercial-scale conditions; 21 CFR 211.165 answers whether the specific dosage forms in a designated batch conform to finished release specifications prior to release.

To maintain strict operational boundaries, this analysis addresses one specific operational job: marking whether Stage 2 protocol completion, concurrent release design, quality-unit finished product release, and Stage 3 continued process verification are present, missing, or unknown for one designated qualification lot. This briefing is not a second-site technology transfer package checklist (for facility comparability, analytical bridging, and supplemental filings under 21 CFR 314.70, see our companion analysis on second-site commercial tech transfer package gaps); it is not a pre-approval inspection (PAI) audit clock briefing (see PAI readiness and launch-critical facility approval timing); it is not an evaluation of Type V facility Drug Master Files versus PAI obligations at contract facilities (see FDA PreCheck Type V facility DMFs versus CDMO CGMP inspections); it is not a sterile fill-finish contamination control strategy (CCS) RFQ comparison (see sterile fill-finish CDMO Annex 1 CCS versus FDA 2004 aseptic RFQs); it is not an audit of CDMO quality agreement contractual red flags (see CDMO quality agreement red flags from FDA inspection findings); and it is not an analytical method transfer acceptance criteria protocol (see analytical method transfer acceptance criteria for new release testing labs). Furthermore, this analysis rejects arbitrary rules of thumb: it does not invent typical PPQ batch counts, manufactured pass rates, commercial search demand metrics, or real-world facility identities.

Stage 2 is process qualification; Stage 3 is routine-production assurance

The regulatory foundation for modern process validation across human pharmaceuticals, animal drugs, and biological products is established in FDA's guidance Process Validation: General Principles and Practices (Revision 1), issued jointly in January 2011 by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM). The Federal Register notice of availability was officially published on 25 January 2011 (76 FR 4360; FR Doc. 2011-1437; Docket No. FDA-2008-D-0559). While FDA guidance documents do not establish legally enforceable responsibilities unless specific statutory or regulatory requirements are cited, the 2011 guidance articulates the Agency's enforcement approach under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act; 21 U.S.C. 351(a)(2)(B)) and binding Current Good Manufacturing Practice (CGMP) regulations in 21 CFR Parts 210 and 211. FDA's public guidance landing page notes 'content current as of 08/24/2018' as an internal website maintenance stamp; the operative regulatory guidance text remains Revision 1 dated January 2011.

The 2011 glossary defines process validation as 'the collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products.' That lifecycle framing replaces the historical premise that validation is a discrete, three-batch qualification milestone. The guidance divides the work into three stages:

• Stage 1 — Process Design: The commercial manufacturing process is defined from knowledge gained through development and scale-up. The 2011 guidance encourages ICH Q8(R2)/Q9/Q10 development, risk-management, and quality-system tools at this stage; it does not recast Stage 1 as a CQA/CPP checklist that later substitutes for lot release.

• Stage 2 — Process Qualification: The process design is evaluated to determine whether it is capable of reproducible commercial manufacture. Stage 2 has two elements: (1) design of the facility and qualification of utilities and equipment, and (2) process performance qualification (PPQ). The 2011 text does not treat installation/operational/performance qualification acronyms as those two elements; PPQ is the second element, not equipment PQ by another name.

• Stage 3 — Continued Process Verification: Ongoing assurance during routine commercial production that the manufacturing process remains in a validated state of control throughout the commercial lifecycle.

A rigorous understanding of this lifecycle makes clear that executing a PPQ protocol and approving its final summary report is strictly an activity inside Stage 2. It is not Stage 3 commercial monitoring. Completing Stage 2 demonstrates that the manufacturing process is capable of reproducible commercial output under qualification conditions; it does not establish the ongoing data collection, statistical trending, or intra- and inter-batch monitoring required during routine commercial production under Stage 3.

A frequent source of commercial misunderstanding stems from a single sentence in Section V of the 2011 guidance: 'Products manufactured during this stage, if acceptable, can be released for distribution.' Commercial and access teams occasionally interpret this statement as blanket authorization that any lot manufactured during a qualification run may be distributed immediately to wholesalers once the protocol is executed. In regulatory context, however, that sentence is an individualized, per-lot acceptability statement. It affirms that drug products manufactured under Stage 2 are not legally barred from commercial distribution merely because they were produced under a qualification protocol—provided that each specific lot complies with all applicable CGMP requirements, satisfies 21 CFR 211.165 laboratory testing, passes 21 CFR 211.192 quality-unit record review, and meets approved application specifications. It does not mean that the PPQ protocol signature block serves as a universal commercial release ticket.

What protocol completion actually records

Process performance qualification is the second element of Stage 2. It combines the qualified facility, utilities, and equipment, along with trained operating personnel, the commercial manufacturing process, routine control procedures, and commercial-grade raw materials and components to manufacture commercial batches. A successful PPQ confirms the validity of the process design and demonstrates that the commercial manufacturing process performs as expected under actual operating conditions. The guidance specifies that a manufacturer must successfully complete PPQ before commencing commercial distribution of the drug product, and that the commercial distribution decision should be supported by data derived from commercial-scale production runs.

Under Section V.B of the 2011 guidance, FDA recommends that a comprehensive written PPQ protocol define the following technical and operational parameters:

• Manufacturing conditions, qualified raw material sources, component specifications, and validated operating limits.

• Detailed data collection protocols, in-process control checkpoints, sampling plans, and pre-established acceptance criteria.

• Heightened sampling plans designed to evaluate intra-batch uniformity and inter-batch reproducibility with statistical confidence across the entire run.

• Statistical methods for analyzing process variability, yield ranges, and finished product quality attribute distribution.

• Explicit procedural provisions for handling deviations, out-of-specification (OOS) investigations, and nonconforming data.

• Documented verification that facility, utility, equipment, and analytical test method validation are complete prior to protocol initiation.

• Formal review and written approval by all appropriate operational departments and the quality control unit prior to executing the protocol.

Execution of a PPQ protocol should follow the commercial manufacturing process and routine procedures. 21 CFR 211.100(b) requires written production and process-control procedures to be followed in execution, with deviations recorded and justified. 21 CFR 211.110(a) requires in-process control procedures that monitor output and validate the performance of manufacturing processes that may cause variability. The 2011 guidance states that the PPQ campaign is executed under those routine CGMP procedures.

Following execution, the 2011 guidance recommends a timely report that states a clear conclusion whether the data indicate the process met the conditions established in the protocol and whether the process is considered to be in a state of control, with appropriate department and quality-unit review and approvals. That report is a Stage 2 study conclusion. It is not, by itself, the 21 CFR 211.165 laboratory determination for the same lot, and it is not Stage 3 continued process verification.

A manufacturing process that uses process analytical technology (PAT) may warrant a different PPQ emphasis on the measurement system and control loop, as the 2011 guidance notes. That different study design does not waive 21 CFR 211.100 written process-control procedures, 21 CFR 211.22 quality-unit approve-or-reject authority, or 21 CFR 211.165 per-batch laboratory determination.

This regulatory separation is reinforced in Footnote 15 of the 2011 guidance, attached to the statement that successful completion of Stage 2 is necessary before commercial distribution. The footnote states that process validation, including process qualification, is legally enforceable under section 501(a)(2)(B) of the FD&C Act, and that FDA regulations require process validation procedures to be established and followed (§ 211.100) before a batch can be distributed (citing 21 CFR 211.22 and 21 CFR 211.165). The commercial-distribution gate in that footnote is therefore the CGMP triad—written process procedures (§ 211.100), quality-unit disposition authority (§ 211.22), and per-batch laboratory determination (§ 211.165)—not the signature on the PPQ summary report.

Biopharma technical teams must also abandon the widespread myth of the 'three consecutive batches' formula. FDA's CGMP Questions and Answers on Production and Process Controls asks whether CGMP requires three successful process-validation batches before an API or finished drug product is released for distribution, and answers no: neither the CGMP regulations nor FDA policy specifies a minimum number of batches. The Agency writes that validating a manufacturing process, or a change to a process, cannot be reduced to so simplistic a formula as the completion of three successful full-scale batches, and that the idea of three validation batches became prevalent in part because of language in past Agency guidance. The current process-validation guidance recommends a product lifecycle approach. A separate Q&A dated 22 May 2024 states that, for human cell and gene therapy products, there is no set minimum number of PPQ batches in 21 CFR 601.20 or in 21 CFR 211.100 and 211.110. Diligence teams should inspect the protocol's scientific and statistical justification rather than filling this worksheet with an arbitrary three-batch quota.

Concurrent release is a rare protocol design, not a standing path

The 2011 guidance glossary defines concurrent release as: 'Releasing for distribution a lot of finished product, manufactured following a qualification protocol, that meets the lot-release criteria established in the protocol, but before the entire study protocol has been executed.' In standard prospective process validation, all qualification batches designated in the PPQ protocol must be fully manufactured, tested, and analyzed, and the PPQ summary report must be formally approved by the quality unit before any commercial distribution begins. Under concurrent release, an individual qualification lot is released into commercial channels while subsequent qualification lots specified in the protocol remain unexecuted or under evaluation.

Section V of the 2011 guidance establishes rigorous boundaries around concurrent release: 'In most cases, the PPQ study needs to be completed successfully and a high degree of assurance achieved before commercial distribution... FDA expects that concurrent release will be used rarely.' The guidance outlines three narrow categories where concurrent release may be considered acceptable:

• Infrequently manufactured products: Processes used infrequently because demand is limited, such as orphan drugs or minor-use and minor-species veterinary drugs.

• Products with short half-lives: Radiopharmaceuticals, including positron emission tomography (PET) drugs.

• Critical drug shortage alleviation: Medically necessary drugs manufactured in coordination with FDA to alleviate a short supply.

Concurrent release cannot be invoked ad hoc when a commercial launch deadline is compressed. Circumstances and rationale should be fully described in the written PPQ protocol. Even when concurrent release is used, each concurrently released lot must still comply with all CGMPs, regulatory approval requirements, and protocol lot-release criteria. The 2011 guidance states that conclusions about a commercial manufacturing process can be made only after the PPQ protocol is fully executed and the data are fully evaluated. Concurrently released lots must also be assessed in light of any negative PPQ study finding, with corrective action under 21 CFR 211.100(a), 21 CFR 211.180(e), and 21 CFR 211.192. That assessment duty is not a standing commercial-release path, and it is not proof that Stage 2 or Stage 3 is complete.

FDA Compliance Policy Guide (CPG) Sec. 490.100, titled 'Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval' (revised 12 March 2004; issued 30 August 1993), is enforcement policy on the timing of certain process-validation activities. It states that new drug applications may be approved by the Center prior to completion of the initial conformance-batch phase, but that manufacture of those initial conformance batches should be successfully completed prior to commercial distribution, except as identified. Those exceptions include certain orphan products, where making unused conformance batches would not be in the public interest, and products with a very short shelf-life or limited use (some radiopharmaceuticals), in which product distribution may have occurred concurrently with the release of each conformance batch. Two boundaries matter for this worksheet: CPG 490.100 does not convert a signed protocol into 21 CFR 211.165 lot release, and it does not address products approved by a Biologics License Application (BLA) or recombinant protein drug products submitted in an NDA.

The EMA–FDA joint Q&As on Quality and GMP aspects of PRIME and Breakthrough Therapy applications (EMA/CHMP/531552/2023) treat concurrent validation / concurrent release of PPQ batches as a case-by-case approach where there is a strong benefit-risk ratio for the patient—limited demand (for example orphan drugs), life-threatening or severely debilitating conditions, short half-lives (for example radiopharmaceuticals), or urgent demand such as a pandemic. Companies are encouraged to engage early with EMA or FDA. The Q&A states that the approach is not meant to alter any expectation for compliance with GMP: the quality system must still ensure that a batch has met its quality specifications and was manufactured under GMP. Available data should support that the process is in a state of control. That joint text confirms concurrent release as an exceptional, discussed design, not a default commercial-release path, and it does not collapse protocol criteria into CGMP lot release.

211.165 and 211.22: the quality unit still owns this lot

The CGMP checkpoint for commercial batch distribution is 21 CFR 211.165 (Testing and release for distribution). This regulation establishes requirements that must be met prior to releasing any individual batch of drug product:

• 211.165(a): For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.

• 211.165(b): There shall be appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.

• 211.165(c): Any sampling and testing plans shall be described in written procedures that shall include the method of sampling and the number of units per batch to be tested; such written procedure shall be followed.

• 211.165(d): Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to assure that batches of drug product meet each appropriate specification and appropriate statistical quality control criteria as a condition for approval and release.

• 211.165(e): The accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented.

• 211.165(f): Drug products that fail to meet established standards or specifications and any other relevant quality control criteria shall be rejected.

Technical teams must not confuse the narrow laboratory timing exception inside 21 CFR 211.165(a) with concurrent PPQ release. Section 211.165(a) provides that where sterility and/or pyrogen testing are conducted on specific batches of short-lived radiopharmaceuticals, those batches may be released prior to completion of sterility and/or pyrogen testing, provided such testing is completed as soon as possible. That in-section exception is not concurrent PPQ release and does not waive identity-and-strength testing.

Under 21 CFR 211.22(a), the quality control unit has the responsibility and authority to approve or reject drug products, including products manufactured, processed, packed, or held under contract by another company, and the authority to review production records to assure that no errors have occurred or that they have been fully investigated. Section 210.3(b)(15) defines the quality control unit as any person or organizational element designated by the firm to be responsible for duties relating to quality control; 21 CFR 211.3 applies that definition in part 211. Under 21 CFR 211.192, all drug-product production and control records, including packaging and labeling records, must be reviewed and approved by the quality control unit to determine compliance with established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy or failure of a batch or any of its components to meet specifications must be thoroughly investigated, whether or not the batch has already been distributed. 21 CFR 211.194(a) requires laboratory records to include complete data derived from all tests necessary to assure compliance with established specifications, and 21 CFR 211.188 requires a complete batch production and control record for each batch produced. Protocol lot-release criteria and the 211.165 laboratory determination are related fields; they are not the same record.

When manufacturing occurs at a contract facility, commercial release authority does not transfer to the CDMO. FDA's guidance Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016) affirms that under 21 CFR 200.10(b) and 21 CFR 211.22(a), the drug product owner's quality unit remains legally responsible for approving or rejecting drug products, including final commercial release. While the contract facility's quality unit must review production records and confirm that the batch was manufactured in compliance with CGMP, the contract facility's sign-off on a PPQ protocol or certificate of analysis is merely an operational input. The owner's quality unit must evaluate complete laboratory and production documentation before issuing formal commercial disposition. A CDMO signature on a PPQ report cannot legally substitute for owner release.

FDA regulatory enforcement treats process qualification, per-batch testing, record review, and ongoing monitoring as distinct asks. Warning Letter 717355 to Seaway Pharma Inc., dated 1 December 2025, is an OTC finished-drug letter—not this worksheet's lot. FDA cited the quality unit for releasing numerous batches before reviewing all test results, for failing to ensure each batch was tested for the strength of active ingredients prior to release (21 CFR 211.165(a)), and for failing to ensure laboratory records included complete data (21 CFR 211.194(a)). Separately, FDA cited 21 CFR 211.100(a) for inadequate written production and process-control procedures and inadequate process validation, stated that successful process-qualification studies are necessary before commercial distribution and that ongoing vigilant oversight of process performance and product quality is necessary thereafter, and asked for both a timeline for performing appropriate PPQ for each marketed drug product and a program for ongoing monitoring of intra-batch and inter-batch variation. The letter is enforcement evidence that those identities are not one checkbox. It is not a real PPQ-package case study, and it is not a typical-rate statistic.

For biological products licensed under Section 351 of the Public Health Service Act, two additional legal identities sit outside Part 211 and must not be collapsed into commercial release. Under 21 CFR 610.1, no lot of any licensed biological product may be released by the manufacturer prior to completion of tests for conformity with applicable standards. Under 21 CFR 610.2, CBER or CDER may require the submission of samples and protocol documentation and notify the manufacturer not to distribute a lot until the Center Director officially releases it. Official agency lot release under 610.2, when invoked, represents a distinct governmental checkpoint that sits on top of manufacturer quality-unit release; it is not satisfied by completing a Stage 2 PPQ protocol.

Stage 3 continued process verification is a different program

Stage 3 Continued Process Verification (CPV) is defined in the 2011 glossary as assuring that during routine production the process remains in a state of control. The goal is continual assurance that the process remains in the validated state during commercial manufacture. FDA maps that program to 21 CFR 211.180(e), which requires that written records be maintained so that data can be used for evaluating, at least annually, the quality standards of each drug product, including review of a representative number of batches and of complaints, recalls, returned or salvaged products, and 211.192 investigations.

Technical teams must not collapse Stage 3 CPV into a once-a-year Annual Product Review (APR) or Product Quality Review (PQR). 21 CFR 211.180(e) requires written records so that data can be used for evaluating, at least annually, the quality standards of each drug product. The 2011 guidance maps CPV to that collection-and-evaluation duty and recommends more than a retrospective annual compilation: an ongoing program to collect and analyze product and process data, statistical trending reviewed by trained personnel, scrutiny of intra-batch and inter-batch variation, and quality-unit review. That is still not a near-real-time release step, and it is not the 211.165 determination for a historical lot.

During the transition from Stage 2 into Stage 3, the 2011 guidance recommends continued monitoring and sampling of process parameters and quality attributes at the level established during process qualification until sufficient data exist to generate variability estimates and to set routine monitoring. Heightened PPQ sampling is therefore not automatically finished by the protocol report. Stage 3 CPV is an ongoing program; it does not release individual lots. Each commercial batch manufactured during Stage 3 still requires independent 21 CFR 211.165 laboratory determination and 21 CFR 211.192 quality-unit record review before distribution.

One fictional qualification lot: present, missing, or unknown

The matrix below is a diligence worksheet for one labeled fictional qualification lot, Lot Q-2026-F1. The lot is hypothetical and cannot be mistaken for an actual commercial batch. No interior PPQ protocol, batch record, certificate of analysis, quality-unit ticket, or CPV plan for this lot was reviewed. The only honest mark for every field is therefore Unknown—not Present inferred from a bound protocol cover, and not Missing inferred from vendor lore or a three-batch rule. An operator substituting real records should recast each row as Present, Missing, or Unknown, and should use N/A for 21 CFR 610.1/610.2 only when the product is not a licensed biologic.

flowchart TD
    A["Labeled fictional qualification lot Q-2026-F1"] --> B{"Is the Stage 2 PPQ protocol fully executed and reported?"}
    B -- Yes --> C["Stage 2 study conclusion is a separate record"]
    B -- No --> D{"Does the approved protocol design concurrent release?"}
    D -- No --> E["Do not treat protocol signature as distribution authorization"]
    D -- Yes --> F["Still check protocol lot-release criteria, CGMP, and application approval"]
    C --> G["21 CFR 211.165 laboratory determination for this lot"]
    F --> G
    G --> H["21 CFR 211.192 and 211.188 production-record review"]
    H --> I["21 CFR 211.22 owner quality-unit disposition"]
    I --> J["Those CGMP records, not the protocol signature, are the commercial-release fields"]
    K["Stage 3 CPV under 21 CFR 211.180(e) is a different ongoing program"]

The table below lists the objective evidence each field needs. For Lot Q-2026-F1, every diligence mark is Unknown because no interior package was reviewed:

When conducting technical due diligence or commercial launch preparation, biopharma quality and CMC teams should implement a four-step verification sequence:

• Verify pre-execution protocol approval: Confirm that the PPQ protocol was approved by the quality control unit prior to execution, and verify whether a formal PPQ summary report has been approved concluding that the process demonstrated a state of control.

• Determine validation design (Prospective vs Concurrent): Check whether the qualification lot was released prospectively or concurrently. If concurrent release was utilized, verify that explicit justification and lot-release criteria were documented in the approved protocol prior to manufacturing.

• Inspect individual lot release packet: Ensure that complete laboratory testing under 21 CFR 211.165 (including active ingredient identity and strength) and batch record review under 21 CFR 211.192 were executed by the owner's quality unit before commercial shipment.

• Audit Stage 3 CPV readiness: Check whether a Stage 3 CPV program actually exists to collect and evaluate process and product data during routine production under 21 CFR 211.180(e). Completing a PPQ protocol is not that ongoing program, and CPV does not itself release this historical lot.

Teams managing broader biopharma technical operations should cross-reference our adjacent analyses: for secondary site onboarding, consult tech transfer package gaps for commercial products; for regulatory inspection scheduling, consult PAI readiness and launch-critical facility approval timing; for facility master file strategy, see FDA PreCheck Type V facility DMFs versus CDMO CGMP inspections; for vendor governance, review CDMO quality agreement red flags from FDA inspection findings; for release testing lab qualification, examine analytical method transfer acceptance criteria for new release testing labs; for sterile operations, consult sterile fill-finish CDMO Annex 1 CCS versus FDA 2004 aseptic RFQs; for regulatory change management, review PACMP strategy for biologic manufacturing site changes and ICH Q12 established conditions for regulatory submissions; and for technical non-approval analysis, see CMC-only Complete Response Letters and commercial launch risk; for Module 3 lifecycle operators after supplements, see eCTD Module 3 lifecycle hygiene on post-approval supplements; for FDA/EMA/non-ICH filing mismatch, see global CMC change-classification mismatch.

Sources

• FDA Guidance for Industry — Process Validation: General Principles and Practices (January 2011, Revision 1) — Comprehensive FDA guidance defining the three-stage process validation lifecycle, Stage 2 process qualification, PPQ protocol expectations, and concurrent release criteria.

• FDA Guidance Landing Page — Process Validation: General Principles and Practices — Official FDA resource page confirming guidance publication and maintenance status under Docket No. FDA-2008-D-0559.

• Federal Register Notice of Availability — Process Validation Guidance (76 FR 4360, 25 January 2011) — Official Federal Register publication notice for the 2011 process validation guidance (FR Doc. 2011-1437).

• 21 CFR 211.165 — Testing and release for distribution — Federal CGMP regulation establishing requirements for finished product laboratory determination of identity, strength, and quality prior to release.

• 21 CFR 211.22 — Responsibilities of quality control unit — Federal CGMP regulation defining the quality control unit's authority to approve or reject drug products, including contract-manufactured lots.

• 21 CFR 211.100 — Written procedures; deviations — Federal CGMP regulation requiring written production and process control procedures and justification of deviations.

• 21 CFR 211.110 — Sampling and testing of in-process materials and drug products — Federal CGMP regulation mandating in-process controls and process performance monitoring to prevent variability.

• 21 CFR 211.180 — General requirements (Records and reports, including § 211.180(e)) — Federal CGMP regulation requiring written records for at-least-annual evaluation of product quality standards.

• 21 CFR 211.192 — Production record review — Federal CGMP regulation requiring quality control unit review and approval of all production and control records prior to batch release.

• 21 CFR 211.188 — Batch production and control records — Federal CGMP regulation governing complete batch production and control records for each manufactured lot.

• 21 CFR 211.194 — Laboratory records — Federal CGMP regulation requiring complete laboratory test data derived from all tests necessary to assure compliance.

• 21 CFR 210.3 — Definitions — Federal CGMP regulation defining quality control unit, batch, lot, and commercial manufacturing terms.

• FDA Guidance for Industry — Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016) — FDA guidance clarifying that drug product owners retain legal responsibility for product release under 21 CFR 211.22(a).

• FDA Compliance Policy Guide Sec. 490.100 — Process Validation Requirements for Pre-Market Approval Products — FDA enforcement policy on validation timing for NDAs and APIs, and its explicit exclusion of BLAs and recombinant proteins.

• FDA CGMP Questions and Answers — Production and Process Controls — Official FDA Q&A rejecting the three-batch validation formula and affirming a risk-based lifecycle approach.

• FDA Warning Letter 717355 — Seaway Pharma Inc. (1 December 2025) — Regulatory enforcement letter demonstrating separate citations for missing 211.165 testing, quality record review, PPQ, and CPV monitoring.

• EMA–FDA Joint Q&As on Quality and GMP Aspects of PRIME / Breakthrough Therapy Applications (2023) — Transatlantic regulatory Q&A addressing concurrent validation and commercial release criteria for accelerated programs.

• 21 CFR 610.1 — Tests prior to release required for each lot — Federal biological product regulation requiring completion of tests for conformity with applicable standards prior to manufacturer release.

• 21 CFR 610.2 — Requests for samples and protocols; official release — Federal biological product regulation authorizing official release by CBER or CDER prior to commercial lot distribution.